公开(公告)号：US20240350530A1

公开(公告)日：2024-10-24

申请号：US18685725

申请日：2022-08-25

Applicant: Amplifica Holdings Group, inc.

Inventor： David K. Rosen ,  William Rassman

IPC: A61K31/728 ,  A61K38/19 ,  A61P17/14

CPC classification number: A61K31/728 ,  A61K38/19 ,  A61P17/14

Abstract: Methods and compositions for stimulating hair growth are disclosed. Compositions for stimulating hair growth include two or more of hyaluronic acid, osteopontin, and another CD44 binding ligand. Methods for stimulating hair growth include administering such composition into the skin of a patient.

公开(公告)号：US12090261B2

公开(公告)日：2024-09-17

申请号：US17526663

申请日：2021-11-15

Applicant: ExThera Medical Corporation

Inventor： Robert S. Ward ,  Keith R. McCrea ,  Lakhmir (Mink) Chawla

IPC: A61K31/727 ,  A61K31/726 ,  A61K31/728 ,  A61K31/737 ,  A61M1/36 ,  A61P7/00 ,  B01J20/24

CPC classification number: A61M1/3689 ,  A61K31/726 ,  A61K31/727 ,  A61K31/728 ,  A61K31/737 ,  A61P7/00 ,  B01J20/24

Abstract: The present invention provides methods and devices for augmenting impaired glycocalyx barrier function in a subject in need thereof by contacting a sample (e.g., blood) obtained from the subject with a glycocalyx-mimetic adsorption media. The adsorption media includes glycosaminoglycan structures and, optionally, proteoglycan core proteins, which are conducive to enhancing and/or restoring the impaired glycocalyx barrier function in a sample. The contacted sample is subsequently separated from the adsorption media, producing a treated sample that can be infused into the subject. Methods and devices for treating a patient suffering from a disease associated with glycocalyx barrier dysfunction are also provided herein.

公开(公告)号：US20240285673A1

公开(公告)日：2024-08-29

申请号：US18403151

申请日：2024-01-03

Applicant: Allergan, Inc.

Inventor： Bereth J. Beard ,  Wendy Blanda ,  David Marsh ,  Joseph G. Vehige ,  Peter Simmons ,  Haixia Liu ,  Steven Matsumoto

IPC: A61K31/728 ,  A61K9/00 ,  A61K31/047 ,  A61K31/205 ,  A61K31/717 ,  A61K47/02 ,  A61K47/12 ,  A61K47/36 ,  A61K47/38

CPC classification number: A61K31/728 ,  A61K9/0048 ,  A61K31/047 ,  A61K31/205 ,  A61K31/717 ,  A61K47/02 ,  A61K47/12 ,  A61K47/36 ,  A61K47/38

Abstract: Embodiments described herein relate to formulations for and methods of use for eye drop formulations comprising carboxymethyl cellulose (CMC) and hyaluronic acid (HA) with an improved distribution on the cornea during blinking.

公开(公告)号：US20240277819A1

公开(公告)日：2024-08-22

申请号：US18560153

申请日：2022-05-11

Applicant: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA

Inventor： Henry DANIELL ,  Robert P. RICCIARDI

IPC: A61K38/48 ,  A61K9/68 ,  A61K31/728 ,  A61K38/16 ,  A61K47/02 ,  A61K47/12 ,  A61K47/26 ,  A61P31/14 ,  A61P31/16

CPC classification number: A61K38/48 ,  A61K9/0058 ,  A61K31/728 ,  A61K38/168 ,  A61K47/02 ,  A61K47/12 ,  A61K47/26 ,  A61P31/14 ,  A61P31/16 ,  C12Y304/17023

Abstract: Compositions and methods for reducing viral load in the oral cavity, particularly Coronavirus such as SARS-CoV-2 and Influenza viral loads are disclosed. Also disclosed are compositions and methods for reducing bacterial or fungal loads in the oral cavity. The compositions comprise a trapping molecule having binding affinity for a protein, glucan, or other molecule on the surface of a virus or microorganism. A carrier appropriate for oral administration, in the form of a chewing gum, long-acting lozenge, or tablet, is further disclosed, to enable easy administration before or after exposure to the infective agent.

公开(公告)号：US20240252525A1

公开(公告)日：2024-08-01

申请号：US18594813

申请日：2024-03-04

Applicant: Matthew Mcleay

Inventor： Matthew Mcleay

IPC: A61K31/7056 ,  A61K9/00 ,  A61K31/02 ,  A61K31/197 ,  A61K31/198 ,  A61K31/409 ,  A61K31/4196 ,  A61K31/7068 ,  A61K31/728 ,  A61K45/06 ,  A61K47/06 ,  A61K47/26 ,  A61P31/14 ,  A61P35/04

CPC classification number: A61K31/7056 ,  A61K9/0043 ,  A61K9/0075 ,  A61K9/0078 ,  A61K31/02 ,  A61K31/197 ,  A61K31/198 ,  A61K31/409 ,  A61K31/4196 ,  A61K31/7068 ,  A61K31/728 ,  A61K45/06 ,  A61K47/06 ,  A61K47/26 ,  A61P31/14 ,  A61P35/04 ,  A61K2300/00

Abstract: Disclosed are pharmaceutical formulations and methods using Verteporfin, Ribavirin, and/or Gemcitabine for use in the treatment of diseases by various routes of administration including inhalation, intratumoral, topical and/or systemic injection administration. This invention relates more specifically to the use of Verteporfin, Ribavirin, Gemcitabine, and/or combinations thereof as an inhaled dry powder treatment for COVID-19 and/or other lung infections, cancer and other non-cancer applications, which may be followed by other treatment regimens including radiation therapy, photodynamic therapy, and/or sonodynamic therapy. These pharmaceutical compositions containing one or more of Verteporfin, Ribavirin, and Gemcitabine may be included in pharmaceutical kits containing the compositions, and to methods for the treatment of cancer and non-cancer diseases with the active agents of the pharmaceutical compositions. The administering of Verteporfin alone or in combination with Ribavirin and Gemcitabine may be followed or co-administered with photodynamic and/or sonodynamic therapy (PDT/SDT).

公开(公告)号：US20240216504A1

公开(公告)日：2024-07-04

申请号：US18148725

申请日：2022-12-30

Applicant: Dong Kyu JIN ,  GREEN CROSS CORPORATION

Inventor： Dong Kyu JIN

IPC: A61K39/395 ,  A61K31/728 ,  A61P7/04 ,  A61P19/02

CPC classification number: A61K39/3955 ,  A61K31/728 ,  A61P7/04 ,  A61P19/02

Abstract: A pharmaceutical composition capable of exhibiting excellent efficacy against hemathrosis by including an anti-TFPI antibody and hyaluronic acid. A use of the pharmaceutical composition is also disclosed. A method for preventing or treating hemathrosis in a subject in need thereof, includes administering to the subject an effective amount of a pharmaceutical composition comprising an anti-TFPI antibody and hyaluronic acid.

公开(公告)号：US20240207368A1

公开(公告)日：2024-06-27

申请号：US18601965

申请日：2024-03-11

Applicant: THE BIOREGENTECH INSTITUTE, INC.

Inventor： MARGARET V. KALMETA

IPC: A61K38/39 ,  A61K31/7004 ,  A61K31/728 ,  A61K33/26 ,  A61K33/34 ,  A61N5/06 ,  A61N5/067 ,  G06T7/00 ,  H01S3/067

CPC classification number: A61K38/39 ,  A61K31/7004 ,  A61K31/728 ,  A61K33/26 ,  A61K33/34 ,  A61N5/06 ,  G06T7/0012 ,  H01S3/06708 ,  A61N2005/0632 ,  A61N2005/0652 ,  A61N5/067 ,  G06T2207/20212 ,  G06T2207/30088

Abstract: Presented herein are compositions that can be administered to a subject having damaged tissue, for example a wound. The compositions are often administered in combination with administration of energy (e.g., laser energy, light from a light emitting diode, radiofrequency (RF) energy, audio frequency energy, etc.) from an energy generating device and/or system to the affected site. The compositions, systems, devices, and methods herein were found to induce wound healing and tissue regeneration.

公开(公告)号：US20240199620A1

公开(公告)日：2024-06-20

申请号：US18389182

申请日：2023-11-13

Applicant: RAPT THERAPEUTICS, INC.

Inventor： Hilary Plake Beck ,  Berenger Biannic ,  Minna Hue Thanh Bui ,  Dennis X. Hu ,  John Michael Ketcham ,  Jay Patrick Powers ,  Maureen Kay Reilly ,  Omar Robles-Resendiz ,  Hunter Paul Shunatona ,  James Ross Walker ,  David Juergen Wustrow ,  Ashkaan Younai ,  Mikhail Zibinsky ,  Jeffrey J. Jackson

IPC: C07D487/04 ,  A61K31/122 ,  A61K31/198 ,  A61K31/235 ,  A61K31/42 ,  A61K31/454 ,  A61K31/4706 ,  A61K31/4985 ,  A61K31/519 ,  A61K31/5377 ,  A61K31/593 ,  A61K31/7135 ,  A61K31/728 ,  A61K45/06

CPC classification number: C07D487/04 ,  A61K31/122 ,  A61K31/198 ,  A61K31/235 ,  A61K31/42 ,  A61K31/454 ,  A61K31/4706 ,  A61K31/4985 ,  A61K31/519 ,  A61K31/5377 ,  A61K31/593 ,  A61K31/7135 ,  A61K31/728 ,  A61K45/06

Abstract: Disclosed herein, inter alia, are compounds and methods of use thereof for the modulation of CCR4 activity.

公开(公告)号：US12011465B1

公开(公告)日：2024-06-18

申请号：US17879746

申请日：2022-08-02

Applicant: Amnio Technology LLC

Inventor： Robert B. Diller ,  Sarah Berglund

IPC: A61K35/50 ,  A61K9/00 ,  A61K9/50 ,  A61K31/728 ,  A61K47/20

CPC classification number: A61K35/50 ,  A61K9/0024 ,  A61K9/5084 ,  A61K31/728 ,  A61K47/20

Abstract: Acellular amnion derived therapeutic compositions are described having a number of various compositional embodiments. An acellular amnion derived therapeutic composition has essentially no live or active amniotic cells. The amniotic cells may be destroyed and the cells and cell debris may be removed from the acellular amnion derived therapeutic composition. An acellular amnion derived therapeutic composition may comprise micronized placental tissue particles, and/or amniotic fluid. An acellular amnion derived therapeutic composition may be a dispersion of micronized amniotic membrane combined with a fluid, such as plasma, saline, amniotic fluid, combinations thereof and the like. An acellular amnion derived therapeutic composition may be combined with a matrix component to form a composite. An acellular amnion derived therapeutic composition may be used in conjunction with a composition comprising viable cells, such as stem cells.

公开(公告)号：US20240189208A1

公开(公告)日：2024-06-13

申请号：US18552341

申请日：2022-04-19

Applicant: NOXELIS ,  FALGAGEN

Inventor： Alexandre ADAMCZEWSKI ,  Gautier LALEVEE

IPC: A61K8/73 ,  A61K8/27 ,  A61K9/00 ,  A61K31/722 ,  A61K31/728 ,  A61K31/737 ,  A61K47/02 ,  A61L27/44 ,  A61Q19/00

CPC classification number: A61K8/736 ,  A61K8/27 ,  A61K8/73 ,  A61K8/735 ,  A61K9/0048 ,  A61K31/722 ,  A61K31/728 ,  A61K31/737 ,  A61K47/02 ,  A61L27/446 ,  A61Q19/00 ,  A61L2400/06 ,  A61L2430/06 ,  A61L2430/34

Abstract: The invention relates to a biocompatible product having a crosslinked matrix, in which a polysaccharide is co-crosslinked with chitosan, a chitosan derivative, or a salt of chitosan, said matrix further comprising a divalent zinc cation.